Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products
Authors:
Open Access
- 3 May 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (5) , e193242
Abstract
Peanut immunotherapy is poised to offer a significant shift in paradigms of care for patients with peanut allergy, and both oral and epicutaneous forms of therapy may be approved in the coming years.1,2 These new products may include a commercial peanut oral immunotherapy (POIT) treatment (AR101; Aimmune Therapeutics) as well as an epicutaneous peanut immunotherapy (EPIT) patch (Viaskin peanut; DBV Technologies). Neither therapy is curative (ie, creates a lasting tolerance allowing ad libitum peanut consumption), although both may offer some increase in the amount of peanut an individual can tolerate before reacting (or the amount at which a reaction will occur) of between 300 and 1000 mg of peanut protein (estimated to reduce the risk of reaction from accidental exposure from products with precautionary labeling by 95% to 99% and, at the upper ranges, protect from a small bite of a peanut-containing product) as well as some possible attenuation of the severity of a reaction on peanut exposure.3-6 However, patients treated with these therapies must still follow strict peanut avoidance and carry emergency medications. How these therapies may ultimately be used in the treatment of peanut allergy is incompletely understood.7 Both therapies have risks of adverse events, including anaphylaxis related to the treatment itself, although the degree to which patients may accept this as a trade-off is unknown.8 To better understand the potential health benefits and economic outcomes (eg, relative costs and value) of these commercial food allergy therapies, we performed Markov modeling with microsimulation and cost-effectiveness analysis.Keywords
This publication has 35 references indexed in Scilit:
- Food allergy: A practice parameter update—2014Journal of Allergy and Clinical Immunology, 2014
- Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trialThe Lancet, 2014
- The Economic Impact of Childhood Food Allergy in the United StatesJAMA Pediatrics, 2013
- Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta‐analysisClinical & Experimental Allergy, 2013
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statementBMJ, 2013
- The natural history of persistent peanut allergyAnnals of Allergy, Asthma & Immunology, 2012
- Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United StatesJournal of Allergy and Clinical Immunology, 2011
- Improving Decision Analyses: Parent Preferences (Utility Values) for Pediatric Health OutcomesThe Journal of Pediatrics, 2009
- Health Economic Evaluations: The Special Case of End-Stage Renal Disease TreatmentMedical Decision Making, 2002
- The natural history of peanut allergyJournal of Allergy and Clinical Immunology, 2001